Skip to main content
. 2015 Feb 4;30(6):788–795. doi: 10.1002/mds.26159

Table 3.

Adverse events (>10% or >2 patients in any ADS‐5102 group)

Adverse Event n (%) Placebo (n = 22) 260 mg ADS‐5102 (n = 20) 340 mg ADS‐5102 (n = 21) 420 mg ADS‐5102 (n = 20)
Constipation 2 (9.1) 7 (35.0) 5 (23.8) 3 (15.0)
Dizziness 1 (4.5) 3 (15.0) 6 (28.6) 3 (15.0)
Hallucination 0 4 (20.0) 5 (23.8) 4 (20.0)
Dry mouth 0 3 (15.0) 4 (19.0) 2 (10.0)
Fall 3 (13.6) 1 (5.0) 3 (14.3) 3 (15.0)
Confusion 1 (4.5) 1 (5.0) 3 (14.3) 2 (10.0)
Headache 1 (4.5) 1 (5.0) 3 (14.3) 1 (5.0)
Nausea 1 (4.5) 1 (5.0) 3 (14.3) 1 (5.0)
Asthenia 1 (4.5) 0 3 (14.3) 1 (5.0)